Activity and Expression Pattern of NF-κB/P65 in Peripheral Blood from Hepatocellular Carcinoma Patients - Link to Hypoxia Inducible Factor -1α

  • Gaballah, Hanaa Hibishy (Medical Biochemistry Department, Faculty of Medicine, Tanta University) ;
  • Zakaria, Soha Said (Medical Biochemistry Department, Faculty of Medicine, Tanta University) ;
  • Ismail, Saber Abdelrahman (Tropical Medicine Department, Faculty of Medicine, Tanta University)
  • Published : 2014.08.30


Background: Hepatocellular carcinoma is a complex and heterogeneous tumor with poor prognosis due to frequent intrahepatic spread and extrahepatic metastasis. The molecular mechanisms underlying HCC pathogenesis still remain obscure. Objectives: We aimed to investigate the abundance and the DNA binding activity of nuclear factor kappa B/p65 subunit in peripheral blood mononuclear cells from patients with HCC and to assess its prognostic significance and association with hypoxia inducible factor one alpha (HIF-$1{\alpha}$) in blood. Subjects and methods: This study was carried out on 40 patients classified equally into liver cirrhosis (group I) and HCC (group II), in addition to 20 healthy volunteers (group III). All groups were subjected to measurement of NF-${\kappa}B$/P65 subunit expression levels by real time-PCR, and DNA binding activity was evaluated by transcription factor binding immunoassay. Serum HIF-$1{\alpha}$ levels were estimated by enzyme-linked immunosorbent assay (ELISA). Significant increase of both the expression level and DNA binding activity of NF-${\kappa}B$/P65 subunit together with serum HIF-1 alpha levels was noted in HCC patients compared to liver cirrhosis and control subjects, with significant positive correlation with parameters for bad prognosis of HCC. In conclusion, NF-${\kappa}B$ signaling is activated in HCC and associated with disease prognosis and with high circulating levels of HIF-1 alpha.


HCC;liver cirrhosis;NF-${\kappa}B$;hypoxia inducible factor one alpha;binding activity


  1. Abdelaziz AO, Elbaz TM, Shousha HI, et al (2014). Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev, 15, 3915-20.
  2. Balermpas P, Michel Y, Wagenblast J, et al (2013). Nuclear $NF-{\kappa}B $ expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy. Int J Radiat Oncol Biol Phys, 86, 785-90.
  3. Beale G, Chattopadhyay D, Gray J, et al (2008). AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 18, 8-200.
  4. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
  5. Bruix J, Sherman M (2005). Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.
  6. Cheng ZX, Wang DW, Liu T, et al (2014). Effects of the HIF-$1{\alpha}$ and $NF-{\kappa}B $ loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep, 31, 1891-8.
  7. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A (2007). The transcription factor nuclear factorkappa B and cancer. Clin Oncol, 19, 154-61.
  8. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma - current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.
  9. Gong JP, Liu CA, Wu CX, et al (2002). Nuclear factor kB activity in patients with acute severe cholangitis. World J Gastroenterol, 8, 346-9.
  10. Gonzalez-Ramos R, Rocco J, Rojas C, et al (2012). Physiologic activation of nuclear factor kappa-B in the endometrium during the menstrual cycle is altered in endometriosis patients. Fertil Steril, 97, 645-51.
  11. Gorlach A, Bonello S (2008). The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem J, 412, 17-9.
  12. Haruki K, Shiba H, Fujiwara Y, et al (2013). Inhibition of nuclear $factor-{\kappa}B$ enhances the antitumor effect of tumor necrosis $factor-{\alpha}$ gene therapy for hepatocellular carcinoma in mice. Surgery, 154, 468-78.
  13. Hoesel B, Schmid JA (2013). The complexity of $NF-{\kappa}B$ signaling in inflammation and cancer. Mol Cancer, 12, 86.
  14. Hung CH, Lee CM, Kuo FY, et al (2008). Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. Liver Int, 28, 339-4.
  15. Johnson PJ (2001). The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis, 5, 145-59.
  16. Kim HR, Lee SH, Jung G (2010). The hepatitis B viral X protein activates NF-kappaB signaling pathway through the upregulation of TBK1. FEBS Lett, 584, 525-30.
  17. Lee SC, Tan HT, Chung MC (2014). Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol, 20, 3112-24.
  18. Lei JY, Wang WT, Yan LN. (2013). Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol, 19, 6077-83.
  19. Lenihan CR, Taylor CT (2013). The impact of hypoxia on cell death pathways. Biochem Soc Trans, 41, 657-63.
  20. Li S, Yao D, Wang L, et al (2011). Expression characteristics of hypoxia-inducible factor-$1{\alpha}$ and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon, 11, 821-8.
  21. Li WW, Wang QC, Song XW, et al (2012). Correlation of the expression of $NF-{\kappa}B $ p65 and hepatic fibrosis in hepatitis patients. Zhonghua Yi Xue Za Zhi, 17, 1886-8.
  22. Luedde T, Schwabe RF (2011). $NF-{\kappa}B $ in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 8, 108-18.
  23. Mimeault M, Batra SK (2013). Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med, 17, 30-54.
  24. Ramakrishna G, Rastogi A, Trehanpati N, et al (2013). From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer, 2, 367-383.
  25. Ren S, Zhang S, Li M, et al (2013). $NF-{\kappa}B$/p65 and c-Rel subunits promote phagocytosis and cytokine secretion by splenic macrophages in cirrhotic patients with hypersplenism. Int J Biochem Cell Biol, 45, 335-43.
  26. Rosmorduc O, Housset C (2010). Hypoxia: a link between fibrogenesis, angiogenesis and carcinogenesis in liver disease. Semin Liver Dis, 30, 258-70.
  27. Sakurai T, Kudo M (2013). Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma. Liver Cancer, 2, 365-6.
  28. Sarkar DK, Jana D, Patil PS, et al (2013). Role of $NF-{\kappa}B$ as a prognostic marker in breast cancer: a pilot study in Indian patients. Indian J Surg Oncol, 4, 242-7.
  29. Semenza GL (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest, 123, 3664-71.
  30. Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60.
  31. Sun W, Guo MM, Han P, et al (2012). Id-1 and the p65 subunit of $NF-{\kappa}B$ promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis, 33, 810-7.
  32. Taylor CT, Cummins EP (2009). The role of NF-kappaB in hypoxia-induced gene expression. Ann N Y Acad Sci, 1177, 178-84.
  33. Tiwari M, Mikuni S, Muto H, Kinjo M (2013). Determination of dissociation constant of the $NF{\kappa}B$ p50/p65 heterodimer using fluorescence cross-correlation spectroscopy in the living cell. Biochem Biophys Res Commun, 5, 430-5.
  34. Troeger JS, Schwabe RF (2011). Hypoxia and hypoxia-inducible factor $1{\alpha}$: potential links between angiogenesis and fibrogenesis in hepatic stellate cells. Liver Int, 31, 143-5.
  35. Unwith S, Zhao H, Hennah L, Ma D (2014). The potential role of HIF on tumour progression and dissemination. Int J Cancer, doi: 10.1002/ijc.28889.
  36. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al (2006). Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription PCR, immuno-histochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res, 12, 3249-56
  37. Van Loo G, Beyaert R. (2011). Negative regulation of $NF-{\kappa}B$ and its involvement in rheumatoid arthritis. Arthritis Res Ther, 31, 221.
  38. Wang L1, Kang F, Li J, Zhang J, Shan B (2013). Overexpression of p65 attenuates celecoxib-induced cell death in MDAMB- 231 human breast cancer cell line. Cancer Cell Int, 13, 14.
  39. Wilkins T, Malcolm JK, Raina D, et al (2010), Hepatitis C: diagnosis and treatment. American Family Physician, 81, 1351-7.
  40. Wong LL, Lam IP, Wong TY, et al (2013). IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and $NF-{\kappa}B$ activation. PLoS One, 8, e68843.
  41. Wu W, Yao D, Wang Y, et al (2010). Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/ p65 specific siRNA. Tumour Biol, 31, 605-11.
  42. Wu W, Yao DF, Qiu LW, et al (2009). Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis. Hepatobiliary Pancreat Dis Int, 8, 504-9.
  43. Xia JT, Chen LZ, Jian WH, et al (2014). MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of $NF-{\kappa}B$ signaling. J Transl Med, 12, 33.
  44. Yokoo H, Yasuda J, Nakanishi K, et al (2011). Clinicopathological significance of nuclear $factor-{\kappa}B$ activation in hepatocellular carcinoma. Hepatol Res, 41, 240-9.
  45. Yoshida T, Hashimura M, Mastumoto T, et al (2013). Transcriptional upregulation of HIF-$1{\alpha}$ by $NF-{\kappa}B$/p65 and its associations with $\beta$-catenin/p300 complexes in endometrial carcinoma cells. Lab Invest, 93, 1184-93.
  46. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 13, 5433-8.
  47. Zhang J, Zhang DL, Jiao XL, Dong Q (2013). S100A4 regulates migration and invasion in hepatocellular carcinoma HepG2 cells via $NF-{\kappa}B$-dependent MMP-9 signal. Eur Rev Med Pharmacol Sci, 17, 2372-82.
  48. Zhang F, Wang Q, Ye L, et al (2010). Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear $factor-{\kappa}B$/p65 in hepatoma cells. J Med Virol, 82, 920-8.
  49. Zhou L, Liu C, Meng FD, et al (2012). Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev, 13, 483-6.

Cited by

  1. Expression Quantitative Trait Loci for CARD8 Contributes to Risk of Two Infection-Related Cancers—Hepatocellular Carcinoma and Cervical Cancer vol.10, pp.7, 2015,
  2. Plasma Nuclear Factor Kappa B and Serum Peroxiredoxin 3 in Early Diagnosis of Hepatocellular Carcinoma vol.16, pp.4, 2015,
  3. Significance of Tissue Expression and Serum Levels of Angiopoietin-like Protein 4 in Breast Cancer Progression: Link to NF-κB /P65 Activity and Pro-Inflammatory Cytokines vol.16, pp.18, 2016,
  4. Determination of hypoxia-inducible factor-1 by using a ratiometric colorimetric test based on click-mediated growth of gold nanoparticles vol.185, pp.10, 2018,